{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:41:56Z","timestamp":1793396516274,"version":"4.5.0"},"reference-count":180,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After fluid administration for vasodilatory shock, vasopressors are commonly infused. Causes of vasodilatory shock include septic shock, post-cardiovascular surgery, post-acute myocardial infarction, postsurgery, other causes of an intense systemic inflammatory response, and drug -associated anaphylaxis. Therapeutic vasopressors are hormones that activate receptors\u2014adrenergic: \u03b11, \u03b12, \u03b21, \u03b22; angiotensin II: AG1, AG2; vasopressin: AVPR1a, AVPR1B, AVPR2; dopamine: DA1, DA2. Vasopressor choice and dose vary widely because of patient and physician practice heterogeneity. Vasopressor adverse effects are excessive vasoconstriction causing organ ischemia\/infarction, hyperglycemia, hyperlactatemia, tachycardia, and tachyarrhythmias. To date, no randomized controlled trial (RCT) of vasopressors has shown a decreased 28-day mortality rate. There is a need for evidence regarding alternative vasopressors as first-line vasopressors. We emphasize that vasopressors should be administered simultaneously with fluid replacement to prevent and decrease duration of hypotension in shock with vasodilation. Norepinephrine is the first-choice vasopressor in septic and vasodilatory shock. Interventions that decrease norepinephrine dose (vasopressin, angiotensin II) have not decreased 28-day mortality significantly. In patients not responsive to norepinephrine, vasopressin or epinephrine may be added. Angiotensin II may be useful for rapid resuscitation of profoundly hypotensive patients. Inotropic agent(s) (e.g., dobutamine) may be needed if vasopressors decrease ventricular contractility. Dopamine has fallen to almost no-use recommendation because of adverse effects; angiotensin II is available clinically; there are potent vasopressors with scant literature (e.g., methylene blue); and the novel V1a agonist selepressin missed on its pivotal RCT primary outcome. In pediatric septic shock, vasopressors, epinephrine, and norepinephrine are recommended equally because there is no clear evidence that supports the use of one vasoactive agent. Dopamine is recommended when epinephrine or norepinephrine is not available. New strategies include perhaps patients will be started on several vasopressors with complementary mechanisms of action, patients may be selected for particular vasopressors according to predictive biomarkers, and novel vasopressors may emerge with fewer adverse effects.<\/jats:p>","DOI":"10.1055\/s-0040-1710320","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:17:01Z","timestamp":1597969021000},"page":"059-077","source":"Crossref","is-referenced-by-count":70,"title":["Vasopressor Therapy in the Intensive Care Unit"],"prefix":"10.1055","volume":"42","author":[{"given":"James A.","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Critical Care Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, United Kingdom"},{"name":"Department of Surgery and Cancer, Intensive Care Unit, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University Health Methodist Hospital, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Critical Care Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Walley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Critical Care Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Kissoon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"A Rhodes","year":"2017","journal-title":"Crit Care Med"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00134-019-05801-z","article-title":"Vasopressor therapy in critically ill patients with shock","volume":"45","author":"J A Russell","year":"2019","journal-title":"Intensive Care Med"},{"issue":"10","key":"ref3","first-page":"1677","article-title":"Physician culture and vasopressin use in septic shock","volume":"13","author":"J A Russell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"ref4","first-page":"1760","article-title":"Epidemiology of vasopressin use for adults with septic shock","volume":"13","author":"E A Vail","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"17","key":"ref5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMe1402066","article-title":"Is there a good MAP for septic shock?","volume":"370","author":"J A Russell","year":"2014","journal-title":"N Engl J Med"},{"key":"ref6","first-page":"CD003709","article-title":"Vasopressors for hypotensive shock","volume":"2","author":"G Gamper","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref7","first-page":"283","article-title":"High versus low blood-pressure target in septic shock","volume":"371","author":"P Asfar","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa1312173","article-title":"High versus low blood-pressure target in patients with septic shock","volume":"370","author":"P Asfar","year":"2014","journal-title":"N Engl J Med"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00134-017-5016-5","article-title":"Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock","volume":"44","author":"F Lamontagne","year":"2018","journal-title":"Intensive Care Med"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"M Singer","year":"2016","journal-title":"JAMA"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"C W Seymour","year":"2016","journal-title":"JAMA"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"J A Russell","year":"2008","journal-title":"N Engl J Med"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/CCM.0000000000002323","article-title":"The Septic Shock 3.0 definition and trials: a vasopressin and septic shock trial experience","volume":"45","author":"J A Russell","year":"2017","journal-title":"Crit Care Med"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.2016.10485","article-title":"Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial","volume":"316","author":"A C Gordon","year":"2016","journal-title":"JAMA"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"A Khanna","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"D Annane","year":"2018","journal-title":"N Engl J Med"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jama.288.7.862","article-title":"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock","volume":"288","author":"D Annane","year":"2002","journal-title":"JAMA"},{"issue":"18","key":"ref18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM198411013111801","article-title":"The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study","volume":"311","author":"C L Sprung","year":"1984","journal-title":"N Engl J Med"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"B Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study","volume":"18","author":"L S Chawla","year":"2014","journal-title":"Crit Care"},{"issue":"01","key":"ref21","first-page":"43","article-title":"Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial","volume":"19","author":"L S Chawla","year":"2017","journal-title":"Crit Care Resusc"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1513\/AnnalsATS.201708-669SD","article-title":"Rationale and design of an adaptive phase 2b\/3 clinical trial of selepressin for adults in septic shock","volume":"15","author":"R J Lewis","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13054-017-1798-7","article-title":"Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients","volume":"21","author":"J A Russell","year":"2017","journal-title":"Crit Care"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1378\/chest.11-2604","article-title":"The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock","volume":"142","author":"A C Gordon","year":"2012","journal-title":"Chest"},{"issue":"21","key":"ref26","first-page":"2063","article-title":"Severe sepsis and septic shock","volume":"369","author":"D C Angus","year":"2013","journal-title":"N Engl J Med"},{"issue":"03","key":"ref27","first-page":"165","article-title":"Arterial norepinephrine changes in patients with septic shock","volume":"38","author":"C R Benedict","year":"1992","journal-title":"Circ Shock"},{"issue":"01","key":"ref28","first-page":"H22","article-title":"Hypoxic and CO hypoxia in dogs: hemodynamics, carotid reflexes, and catecholamines","volume":"236","author":"J T Sylvester","year":"1979","journal-title":"Am J Physiol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/01.CCM.0000048621.36569.69","article-title":"Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia","volume":"31","author":"M Bucher","year":"2003","journal-title":"Crit Care Med"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1164\/rccm.200903-0332OC","article-title":"Beta2-adrenergic receptor gene polymorphism is associated with mortality in septic shock","volume":"181","author":"T A Nakada","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/CCM.0b013e318218665a","article-title":"Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock","volume":"39","author":"T A Nakada","year":"2011","journal-title":"Crit Care Med"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.10-2517","article-title":"Leucyl\/cystinyl aminopeptidase gene variants in septic shock","volume":"139","author":"T A Nakada","year":"2011","journal-title":"Chest"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0272-6386(88)80170-7","article-title":"Vasoactive hormones in the renal response to systemic sepsis","volume":"11","author":"A D Cumming","year":"1988","journal-title":"Am J Kidney Dis"},{"issue":"27","key":"ref34","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","article-title":"The L-arginine-nitric oxide pathway","volume":"329","author":"S Moncada","year":"1993","journal-title":"N Engl J Med"},{"issue":"15","key":"ref35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jama.1996.03530390058035","article-title":"Nitric oxide and septic shock","volume":"275","author":"J P Cobb","year":"1996","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2006.12.004","article-title":"Prostacyclin in sepsis: a systematic review","volume":"83","author":"E M Zardi","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vph.2010.12.002","article-title":"Prostacyclin, not only nitric oxide, is a mediator of the vasorelaxation induced by acetylcholine in aortas from rats submitted to cecal ligation and perforation (CLP)","volume":"54","author":"A V Ara\u00fajo","year":"2011","journal-title":"Vascul Pharmacol"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","article-title":"Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock","volume":"32","author":"A L\u00f3pez","year":"2004","journal-title":"Crit Care Med"},{"issue":"13","key":"ref39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM199703273361303","article-title":"The effects of ibuprofen on the physiology and survival of patients with sepsis","volume":"336","author":"G R Bernard","year":"1997","journal-title":"N Engl J Med"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.chest.2017.03.035","article-title":"Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis","volume":"152","author":"P Caironi","year":"2017","journal-title":"Chest"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13054-016-1361-y","article-title":"Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients","volume":"20","author":"O H Lundberg","year":"2016","journal-title":"Crit Care"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2197-425X-1-3","article-title":"Epitope specificity of anti-adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model","volume":"1","author":"J Struck","year":"2013","journal-title":"Intensive Care Med Exp"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2197-425X-1-2","article-title":"Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock","volume":"1","author":"K Wagner","year":"2013","journal-title":"Intensive Care Med Exp"},{"issue":"23","key":"ref44","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis","volume":"376","author":"C W Seymour","year":"2017","journal-title":"N Engl J Med"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCM.0b013e3181feeb15","article-title":"Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality","volume":"39","author":"J H Boyd","year":"2011","journal-title":"Crit Care Med"},{"issue":"12","key":"ref46","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/CCM.0000000000001829","article-title":"Early liberal fluids for sepsis patients are harmful","volume":"44","author":"K Genga","year":"2016","journal-title":"Crit Care Med"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00134-017-4746-8","article-title":"How much excess fluid impairs outcome of sepsis?","volume":"43","author":"K R Genga","year":"2017","journal-title":"Intensive Care Med"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/CCM.0000000000003779","article-title":"The restrictive IV fluid trial in severe sepsis and septic shock (RIFTS): a randomized pilot study","volume":"47","author":"K A Corl","year":"2019","journal-title":"Crit Care Med"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"A Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"10","key":"ref50","first-page":"995","article-title":"Early, goal-directed therapy for septic shock - a patient-level meta-analysis","volume":"377","author":"D C Angus","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1164\/rccm.201806-1034OC","article-title":"Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial","volume":"199","author":"C Permpikul","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1164\/rccm.201901-0083ED","article-title":"Early may be better: early low-dose norepinephrine in septic shock","volume":"199","author":"J A Russell","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref53","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/s41591-018-0213-5","article-title":"The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care","volume":"24","author":"M Komorowski","year":"2018","journal-title":"Nat Med"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/SHK.0000000000001281","article-title":"Incidence, patient characteristics, mode of drug delivery, and outcomes of septic shock patients treated with vasopressors in the arise trial","volume":"52","author":"A A Udy","year":"2019","journal-title":"Shock"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","article-title":"A comparison of epinephrine and norepinephrine in critically ill patients","volume":"34","author":"J A Myburgh","year":"2008","journal-title":"Intensive Care Med"},{"issue":"09","key":"ref56","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"D De Backer","year":"2010","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(07)61344-0","article-title":"Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial","volume":"370","author":"D Annane","year":"2007","journal-title":"Lancet"},{"issue":"20","key":"ref58","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1001\/jama.2011.1615","article-title":"Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis","volume":"306","author":"A J Walkey","year":"2011","journal-title":"JAMA"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/SHK.0000000000001022","article-title":"Vasopressor cumulative dose requirement and risk of early death during septic shock: an analysis from the EPISS Cohort","volume":"49","author":"A Dargent","year":"2018","journal-title":"Shock"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1378\/chest.12-1106","article-title":"Survival after shock requiring high-dose vasopressor therapy","volume":"143","author":"S M Brown","year":"2013","journal-title":"Chest"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jcrc.2014.04.008","article-title":"Limited echocardiography-guided therapy in subacute shock is associated with change in management and improved outcomes","volume":"29","author":"H D Kanji","year":"2014","journal-title":"J Crit Care"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jamia\/ocw138","article-title":"Understanding vasopressor intervention and weaning: risk prediction in a public heterogeneous clinical time series database","volume":"24","author":"M Wu","year":"2017","journal-title":"J Am Med Inform Assoc"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0885066617716396","article-title":"Hemodynamic instability secondary to vasopressin withdrawal in septic shock","volume":"34","author":"B D Bissell","year":"2019","journal-title":"J Intensive Care Med"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0885066617714209","article-title":"Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock","volume":"34","author":"D A Hammond","year":"2019","journal-title":"J Intensive Care Med"},{"issue":"13","key":"ref65","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.2014.2637","article-title":"Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012","volume":"311","author":"K M Kaukonen","year":"2014","journal-title":"JAMA"},{"issue":"09","key":"ref66","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.201311-2097OC","article-title":"Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill","volume":"189","author":"A Linder","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1097\/CCM.0000000000000503","article-title":"Long-term (10-year) mortality of younger previously healthy patients with severe sepsis\/septic shock is worse than that of patients with nonseptic critical illness and of the general population","volume":"42","author":"A Linder","year":"2014","journal-title":"Crit Care Med"},{"issue":"08","key":"ref68","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1097\/CCM.0000000000001843","article-title":"Short-term organ dysfunction is associated with long-term (10-Yr) mortality of septic shock","volume":"44","author":"A Linder","year":"2016","journal-title":"Crit Care Med"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/CCM.0000000000003023","article-title":"The impact of acute organ dysfunction on long-term survival in sepsis","volume":"46","author":"A Schuler","year":"2018","journal-title":"Crit Care Med"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.107.728840","article-title":"Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease","volume":"118","author":"C B Overgaard","year":"2008","journal-title":"Circulation"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13613-018-0448-9","article-title":"Mean arterial pressure and mortality in patients with distributive shock: a retrospective analysis of the MIMIC-III database","volume":"8","author":"J L Vincent","year":"2018","journal-title":"Ann Intensive Care"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00134-018-5218-5","article-title":"The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients","volume":"44","author":"K Maheshwari","year":"2018","journal-title":"Intensive Care Med"},{"issue":"13","key":"ref73","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/jama.1953.03690130014003","article-title":"Arterenol in treatment of shock","volume":"152","author":"A J Miller","year":"1953","journal-title":"J Am Med Assoc"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"e0129305","DOI":"10.1371\/journal.pone.0129305","article-title":"Vasopressors for the treatment of septic shock: systematic review and meta-analysis","volume":"10","author":"T Avni","year":"2015","journal-title":"PLoS One"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-019-0498-7","article-title":"Current use of vasopressors in septic shock","volume":"9","author":"T WL Scheeren","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/1060028019843664","article-title":"Norepinephrine and vasopressin compared with norepinephrine and epinephrine in adults with septic shock","volume":"53","author":"B E Menich","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00134-012-2468-5","article-title":"Recommendations for sepsis management in resource-limited settings","volume":"38","author":"M W D\u00fcnser","year":"2012","journal-title":"Intensive Care Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.1910.sp001392","article-title":"Chemical structure and sympathomimetic action of amines","volume":"41","author":"G Barger","year":"1910","journal-title":"J Physiol"},{"key":"ref80","first-page":"170","article-title":"Modification by reserpine of the action of sympathomimetic amines in spinal cats; a classification of sympathomimetic amines","volume":"138","author":"U Trendelenburg","year":"1962","journal-title":"J Pharmacol Exp Ther"},{"key":"ref81","first-page":"181","article-title":"Effect of cocaine, denervation and decentralization on the response of the nictitating membrane to various sympathomimetic amines","volume":"138","author":"U Trendelenburg","year":"1962","journal-title":"J Pharmacol Exp Ther"},{"issue":"03","key":"ref82","first-page":"406","article-title":"Cardiovascular effects of sympathomimetic bronchodilators; epinephrine, ephedrine, pseudoephedrine, isoproterenol, methoxyphenamine and isoprophenamine","volume":"122","author":"D M Aviado Jr","year":"1958","journal-title":"J Pharmacol Exp Ther"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI101270","article-title":"The cardio-circulatory effects in man of neo-synephrin (1-alpha-hydroxy-beta-methylamino-3-hydroxy-ethylbenzene hydrochloride)","volume":"21","author":"A Keys","year":"1942","journal-title":"J Clin Invest"},{"issue":"04","key":"ref84","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00637623","article-title":"Pharmacokinetics of 3H-phenylephrine in man","volume":"21","author":"J H Hengstmann","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/cc7121","article-title":"Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial","volume":"12","author":"A Morelli","year":"2008","journal-title":"Crit Care"},{"key":"ref86","first-page":"122","article-title":"The action of sympathomimetic amines on isometric contraction and phosphorylase activity of the isolated rat heart","volume":"127","author":"W R Kukovetz","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"ref87","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2017.2841","article-title":"Association between US norepinephrine shortage and mortality among patients with septic shock","volume":"317","author":"E Vail","year":"2017","journal-title":"JAMA"},{"key":"ref88","first-page":"271","article-title":"Peripheral vascular and other effects of dopamine infusions in man","volume":"27","author":"M J Allwood","year":"1964","journal-title":"Clin Sci"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/cs0630361","article-title":"Abolition, by dopamine blockade, of the natriuretic response produced by lower-body positive pressure","volume":"63","author":"E D Bennett","year":"1982","journal-title":"Clin Sci (Lond)"},{"issue":"06","key":"ref90","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s001340050616","article-title":"The effects of low-dose dopamine infusions on haemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline","volume":"24","author":"R N Juste","year":"1998","journal-title":"Intensive Care Med"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1378\/chest.123.4.1266","article-title":"Bad medicine: low-dose dopamine in the ICU","volume":"123","author":"C L Holmes","year":"2003","journal-title":"Chest"},{"issue":"04","key":"ref92","first-page":"S11","article-title":"The use of low doses of dopamine in intensive care medicine","volume":"92","author":"V D'Orio","year":"1984","journal-title":"Arch Int Physiol Biochim"},{"issue":"05","key":"ref93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1042\/cs0780503","article-title":"Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man","volume":"78","author":"N V Olsen","year":"1990","journal-title":"Clin Sci (Lond)"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1600-6143.2003.00268.x","article-title":"Prevention of cold-preservation injury of cultured endothelial cells by catecholamines and related compounds","volume":"4","author":"B Yard","year":"2004","journal-title":"Am J Transplant"},{"issue":"10","key":"ref95","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.2009.1310","article-title":"Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial","volume":"302","author":"P Schnuelle","year":"2009","journal-title":"JAMA"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/CCM.0000000000000958","article-title":"Management of the potential organ donor in the ICU: Society of Critical Care Medicine\/American College of Chest Physicians\/Association of Organ Procurement Organizations consensus statement","volume":"43","author":"R M Kotloff","year":"2015","journal-title":"Crit Care Med"},{"issue":"11","key":"ref97","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s001340050747","article-title":"Dopamine clearance in critically ill patients","volume":"24","author":"R N Juste","year":"1998","journal-title":"Intensive Care Med"},{"issue":"06","key":"ref98","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0022-5223(98)70049-2","article-title":"Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent","volume":"116","author":"M Argenziano","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1152\/ajplegacy.1975.229.6.1649","article-title":"Renovascular resistance and noradrenaline","volume":"229","author":"L Bomzon","year":"1975","journal-title":"Am J Physiol"},{"issue":"03","key":"ref100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000542-200203000-00011","article-title":"Beneficial effects of short-term vasopressin infusion during severe septic shock","volume":"96","author":"B M Patel","year":"2002","journal-title":"Anesthesiology"},{"issue":"11","key":"ref101","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s00134-006-0378-0","article-title":"Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial","volume":"32","author":"F Lauzier","year":"2006","journal-title":"Intensive Care Med"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40560-018-0344-2","article-title":"Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital","volume":"6","author":"J A Russell","year":"2018","journal-title":"J Intensive Care"},{"issue":"06","key":"ref103","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","article-title":"Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials","volume":"45","author":"M Nagendran","year":"2019","journal-title":"Intensive Care Med"},{"issue":"18","key":"ref104","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2018.4528","article-title":"Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis","volume":"319","author":"W F McIntyre","year":"2018","journal-title":"JAMA"},{"issue":"01","key":"ref105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/ALN.0000000000001434","article-title":"Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial","volume":"126","author":"L A Hajjar","year":"2017","journal-title":"Anesthesiology"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CCM.0000000000001380","article-title":"A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in Ovine Septic Shock","volume":"44","author":"X He","year":"2016","journal-title":"Crit Care Med"},{"issue":"07","key":"ref107","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1097\/CCM.0000000000000300","article-title":"The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*","volume":"42","author":"M O Maybauer","year":"2014","journal-title":"Crit Care Med"},{"issue":"01","key":"ref108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40981-016-0072-3","article-title":"Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: a case report","volume":"3","author":"T Mizota","year":"2017","journal-title":"JA Clin Rep"},{"issue":"10","key":"ref109","doi-asserted-by":"crossref","first-page":"H1245","DOI":"10.1152\/ajpheart.00390.2012","article-title":"Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis","volume":"303","author":"S Rehberg","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/CCM.0b013e3181fa3898","article-title":"Role of selective V1a receptor agonism in ovine septic shock","volume":"39","author":"S Rehberg","year":"2011","journal-title":"Crit Care Med"},{"issue":"10","key":"ref111","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1097\/CCM.0b013e3181ef4694","article-title":"Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock","volume":"38","author":"S Rehberg","year":"2010","journal-title":"Crit Care Med"},{"issue":"05","key":"ref112","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"A J Sanyal","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"ref113","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s00134-018-5267-9","article-title":"Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial","volume":"44","author":"Z M Liu","year":"2018","journal-title":"Intensive Care Med"},{"issue":"11","key":"ref114","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s00134-018-5290-x","article-title":"Terlipressin or norepinephrine, or both in septic shock?","volume":"44","author":"J M\u00e5rtensson","year":"2018","journal-title":"Intensive Care Med"},{"issue":"01","key":"ref115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40256-018-0297-9","article-title":"FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock","volume":"19","author":"F Senatore","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"issue":"01","key":"ref116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13613-019-0536-5","article-title":"Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial","volume":"9","author":"K R Ham","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"01","key":"ref117","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.1971.tb00565.x","article-title":"Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states","volume":"2","author":"G D\u00fcsterdieck","year":"1971","journal-title":"Eur J Clin Invest"},{"issue":"06","key":"ref118","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","article-title":"Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous Angiotensin II","volume":"46","author":"J A Tumlin","year":"2018","journal-title":"Crit Care Med"},{"issue":"01","key":"ref119","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13054-018-2202-y","article-title":"Angiotensin converting enzyme defects in shock: implications for future therapy","volume":"22","author":"L S Chawla","year":"2018","journal-title":"Crit Care"},{"issue":"12","key":"ref120","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1097\/CCM.0b013e318186a299","article-title":"Angiotensin converting enzyme insertion\/deletion genetic polymorphism: its impact on renal function in critically ill patients","volume":"36","author":"D du Cheyron","year":"2008","journal-title":"Crit Care Med"},{"issue":"01","key":"ref121","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/CCM.0000000000002797","article-title":"Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury","volume":"46","author":"Y R Lankadeva","year":"2018","journal-title":"Crit Care Med"},{"issue":"01","key":"ref122","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.kint.2016.02.017","article-title":"Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury","volume":"90","author":"Y R Lankadeva","year":"2016","journal-title":"Kidney Int"},{"issue":"17","key":"ref123","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","article-title":"Levosimendan for the prevention of acute organ dysfunction in sepsis","volume":"375","author":"A C Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"08","key":"ref124","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","article-title":"Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial","volume":"199","author":"D B Antcliffe","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","article-title":"Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study","volume":"4","author":"E E Davenport","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"11","key":"ref126","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/CCM.0000000000001853","article-title":"Elevated plasma angiopoietin-2 levels are associated with fluid overload, organ dysfunction, and mortality in human septic shock","volume":"44","author":"J Fisher","year":"2016","journal-title":"Crit Care Med"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/ajh\/hpx167","article-title":"Renin-angiotensin-aldosterone system parameters as biomarker in heart failure patients with preserved ejection fraction: focus on angiotensinogen","volume":"31","author":"E Uijl","year":"2018","journal-title":"Am J Hypertens"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cca.2014.10.031","article-title":"Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?","volume":"443","author":"M Emdin","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"05","key":"ref129","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3892\/etm.2014.1566","article-title":"Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis","volume":"7","author":"W Zhang","year":"2014","journal-title":"Exp Ther Med"},{"issue":"02","key":"ref130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock","volume":"358","author":"C L Sprung","year":"2008","journal-title":"N Engl J Med"},{"issue":"18","key":"ref131","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc1803563","article-title":"Long-term outcomes of the ADRENAL trial","volume":"378","author":"B Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"ref132","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/CCM.0000000000003889","article-title":"Why my steroid trials in septic shock were \u201cpositive\u201d","volume":"47","author":"D Annane","year":"2019","journal-title":"Crit Care Med"},{"issue":"12","key":"ref133","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1097\/CCM.0000000000003834","article-title":"Why the adjunctive corticosteroid treatment in critically Ill Patients With Septic Shock (ADRENAL) trial did not show a difference in mortality","volume":"47","author":"B Venkatesh","year":"2019","journal-title":"Crit Care Med"},{"issue":"12","key":"ref134","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1097\/CCM.0000000000004038","article-title":"Toward increased understanding of the steroid controversy in septic shock","volume":"47","author":"J A Russell","year":"2019","journal-title":"Crit Care Med"},{"issue":"03","key":"ref135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1067\/mai.2002.122154","article-title":"Glucocorticoid effects on the beta-adrenergic receptor-adenylyl cyclase system of human airway epithelium","volume":"109","author":"M O Aksoy","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"01","key":"ref136","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1378\/chest.15-1703","article-title":"Lactic acidosis in sepsis: it's not all anaerobic: implications for diagnosis and management","volume":"149","author":"B Suetrong","year":"2016","journal-title":"Chest"},{"issue":"04","key":"ref137","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/00000542-200110000-00025","article-title":"Attenuation of lung inflammation by adrenergic agonists in murine acute lung injury","volume":"95","author":"V K Dhingra","year":"2001","journal-title":"Anesthesiology"},{"issue":"03","key":"ref138","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/CCM.0b013e3181961ace","article-title":"Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock","volume":"37","author":"J A Russell","year":"2009","journal-title":"Crit Care Med"},{"issue":"04","key":"ref139","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jcrc.2008.04.002","article-title":"Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study","volume":"23","author":"S R Bauer","year":"2008","journal-title":"J Crit Care"},{"issue":"05","key":"ref140","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1378\/chest.14-0986","article-title":"Atrial fibrillation during sepsis: a determinant of long-term outcomes?","volume":"146","author":"Y C Lau","year":"2014","journal-title":"Chest"},{"issue":"06","key":"ref141","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamacardio.2016.2181","article-title":"Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis","volume":"1","author":"A J Walkey","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"16","key":"ref142","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"A Morelli","year":"2013","journal-title":"JAMA"},{"issue":"05","key":"ref143","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40261-019-00762-z","article-title":"Benefits of beta-blockade in sepsis and septic shock: a systematic review","volume":"39","author":"Y R Lee","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"07","key":"ref144","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s00134-003-1810-3","article-title":"Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function","volume":"29","author":"H Morimatsu","year":"2003","journal-title":"Intensive Care Med"},{"issue":"08","key":"ref145","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1053-2498(99)00038-8","article-title":"Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation","volume":"18","author":"M Argenziano","year":"1999","journal-title":"J Heart Lung Transplant"},{"issue":"19","key":"ref146","first-page":"II182","article-title":"Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery","volume":"100","author":"E B Rosenzweig","year":"1999","journal-title":"Circulation"},{"issue":"01","key":"ref147","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0003-4975(99)01197-2","article-title":"Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock","volume":"69","author":"D L Morales","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"03","key":"ref148","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0003-4975(02)04408-9","article-title":"A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass","volume":"75","author":"D L Morales","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1749-8090-8-49","article-title":"The effect of vasopressin on the hemodynamics in CABG patients","volume":"8","author":"H Yimin","year":"2013","journal-title":"J Cardiothorac Surg"},{"issue":"01","key":"ref150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/CCM.0000000000001441","article-title":"Selepressin in septic shock: a step toward decatecholaminization?","volume":"44","author":"P Asfar","year":"2016","journal-title":"Crit Care Med"},{"issue":"06","key":"ref151","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/CCM.0000000000000212","article-title":"The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial","volume":"42","author":"A C Gordon","year":"2014","journal-title":"Crit Care Med"},{"issue":"18","key":"ref152","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","article-title":"Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study","volume":"107","author":"M W D\u00fcnser","year":"2003","journal-title":"Circulation"},{"issue":"02","key":"ref153","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"B Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref154","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamapediatrics.2017.5208","article-title":"Defining pediatric sepsis","volume":"172","author":"L J Schlapbach","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"06","key":"ref155","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/CCM.0000000000002425","article-title":"American College of Critical Care medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock","volume":"45","author":"A L Davis","year":"2017","journal-title":"Crit Care Med"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(16)00148-3","article-title":"New WHO guidelines on emergency triage assessment and treatment","volume":"387","author":"T Duke","year":"2016","journal-title":"Lancet"},{"issue":"05","key":"ref157","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1542\/peds.2013-3871","article-title":"Improving adherence to PALS septic shock guidelines","volume":"133","author":"R Paul","year":"2014","journal-title":"Pediatrics"},{"issue":"02","key":"ref158","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1542\/peds.2012-0094","article-title":"Adherence to PALS sepsis guidelines and hospital length of stay","volume":"130","author":"R Paul","year":"2012","journal-title":"Pediatrics"},{"issue":"11","key":"ref159","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/CCM.0000000000001260","article-title":"Double-blind prospective randomized controlled trial of dopamine versus epinephrine as first-line vasoactive drugs in pediatric septic shock","volume":"43","author":"A M Ventura","year":"2015","journal-title":"Crit Care Med"},{"issue":"11","key":"ref160","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1097\/PCC.0000000000000954","article-title":"Double-blind randomized clinical trial comparing dopamine and epinephrine in pediatric fluid-refractory hypotensive septic shock","volume":"17","author":"K N Ramaswamy","year":"2016","journal-title":"Pediatr Crit Care Med"},{"issue":"09","key":"ref161","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00431-018-3195-x","article-title":"Epinephrine versus dopamine in neonatal septic shock: a double-blind randomized controlled trial","volume":"177","author":"K Baske","year":"2018","journal-title":"Eur J Pediatr"},{"issue":"03","key":"ref162","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1590\/1806-9282.60.03.008","article-title":"Norepinephrine infusion increases urine output in children under sedative and analgesic infusion","volume":"60","author":"J Piva","year":"2014","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"07","key":"ref163","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1164\/rccm.200902-0221OC","article-title":"Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial","volume":"180","author":"K Choong","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref164","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.2223\/JPED.1711","article-title":"Hemodynamic and metabolic effects of vasopressin infusion in children with shock","volume":"83","author":"E Baldasso","year":"2007","journal-title":"J Pediatr (Rio J)"},{"issue":"03","key":"ref165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00134-007-0971-x","article-title":"Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children","volume":"34","author":"D Yildizdas","year":"2008","journal-title":"Intensive Care Med"},{"issue":"10","key":"ref166","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/PEC.0b013e31826cebe6","article-title":"Beneficial effects of levosimendan in infants with sepsis-associated cardiac dysfunction: report of 2 cases","volume":"28","author":"P Papoff","year":"2012","journal-title":"Pediatr Emerg Care"},{"issue":"03","key":"ref167","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.PCC.0000074278.30462.73","article-title":"Milrinone in meningococcal sepsis","volume":"4","author":"N Rich","year":"2003","journal-title":"Pediatr Crit Care Med"},{"issue":"01","key":"ref168","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13054-018-2254-z","article-title":"When and how to use predictive biomarkers for corticosteroid treatment of septic shock","volume":"22","author":"J A Russell","year":"2018","journal-title":"Crit Care"},{"issue":"03","key":"ref169","first-page":"343","article-title":"The role of genomics to identify biomarkers and signaling molecules during severe sepsis","volume":"82","author":"J J Douglas","year":"2016","journal-title":"Minerva Anestesiol"},{"issue":"01","key":"ref170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13054-019-2420-y","article-title":"Broad spectrum vasopressors: a new approach to the initial management of septic shock?","volume":"23","author":"L S Chawla","year":"2019","journal-title":"Crit Care"},{"issue":"10","key":"ref171","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/CCM.0000000000003276","article-title":"Deresuscitation of patients with iatrogenic fluid overload is associated with reduced mortality in critical illness","volume":"46","author":"J A Silversides","year":"2018","journal-title":"Crit Care Med"},{"issue":"01","key":"ref172","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13613-019-0532-9","article-title":"Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis","volume":"9","author":"Y Wang","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"13","key":"ref173","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.11825","article-title":"Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial","volume":"322","author":"A A Fowler III","year":"2019","journal-title":"JAMA"},{"issue":"01","key":"ref174","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13063-019-3254-2","article-title":"The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial","volume":"20","author":"D N Hager","year":"2019","journal-title":"Trials"},{"issue":"02","key":"ref175","first-page":"119","article-title":"Vitamin C, hydrocortisone and thiamine in patients with septic shock (VITAMINS) trial: study protocol and statistical analysis plan","volume":"21","author":"T Fujii","year":"2019","journal-title":"Crit Care Resusc"},{"issue":"11","key":"ref177","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/CCM.0000000000003803","article-title":"Clinician perception of a machine learning-based early warning system designed to predict severe sepsis and septic shock","volume":"47","author":"J C Ginestra","year":"2019","journal-title":"Crit Care Med"},{"issue":"12","key":"ref178","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1007\/s00134-018-5306-6","article-title":"Innovation and safety in critical care: should we collaborate with the industry? Pro","volume":"44","author":"A C Gordon","year":"2018","journal-title":"Intensive Care Med"},{"issue":"05","key":"ref179","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1164\/rccm.201604-0862CP","article-title":"Potentially inadvertent immunomodulation: norepinephrine use in sepsis","volume":"194","author":"R F Stolk","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref180","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/00003246-199609000-00024","article-title":"Anterior pituitary function during critical illness and dopamine treatment","volume":"24","author":"G Van den Berghe","year":"1996","journal-title":"Crit Care Med"},{"issue":"05","key":"ref182","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000318531","article-title":"Vasopressin and its immune effects in septic shock","volume":"2","author":"J A Russell","year":"2010","journal-title":"J Innate Immun"},{"issue":"04","key":"ref183","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/cc7990","article-title":"Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study","volume":"13","author":"A Morelli","year":"2009","journal-title":"Crit Care"},{"issue":"10","key":"ref184","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/00003246-200110000-00002","article-title":"Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study","volume":"29","author":"M Y Kirov","year":"2001","journal-title":"Crit Care Med"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1710320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T23:33:11Z","timestamp":1611444791000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1710320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":180,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,23]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1710320","relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}